Clinical Trial Update: Onvansertib in Combination With NALIRIFOX for First Line Treatment of Advanced Pancreatic Cancer [Phase 1, Phase 2]

View source ↗

Summary

An ongoing Phase 1/2 trial is evaluating Onvansertib in combination with NALIRIFOX for first-line treatment of advanced pancreatic cancer; the study is currentl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Onivyde (irinotecan hydrochloride liposome injection)
• Onvansertib (onvansertib)

Snippet

Sponsor: University of Kansas Medical Center | Conditions: Pancreatic Cancer | Phase 1, Phase 2 | Status: RECRUITING